Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms

Pharmiweb.com RSS Feed Pharmiweb.com RSS Feeds

Pharmiweb.com RSS Feed PharmiWeb Candidate Blog

Pharmiweb.com RSS Feed PharmiWeb Client Blog

Advertising

Press Release

Global Melanocortin Receptor 4 (MC4R) Pipeline Review, H2 2016 Featuring AstraZeneca, Mallinckrodt, Obexia, Palatin Technologies, Pfizer & Retrophin - Research and Markets

Research and Markets
Posted on: 27 Oct 16

Research and Markets has announced the addition of the "Melanocortin Receptor 4 (MC4R) - Pipeline Review, H2 2016" report to their offering.

Melanocortin Receptor 4 (MC4R) pipeline Target constitutes close to 12 molecules. Out of which approximately 10 molecules are developed by Companies and remaining by the Universities/Institutes. The molecules developed by Companies in Phase III, Phase II and Preclinical stages are 2, 1 and 7 respectively. Similarly, the Universities portfolio in Discovery stages comprises 2 molecules, respectively.

Melanocortin Receptor 4 (MC4R) - Pipeline Review, H2 2016, outlays comprehensive information on the Melanocortin Receptor 4 (MC4R) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews key players involved in Melanocortin Receptor 4 (MC4R) targeted therapeutics development, features dormant and discontinued projects and latest news and press releases.

Key Topics Covered:

  1. Introduction
  2. Melanocortin Receptor 4 Overview
  3. Therapeutics Development
  4. Pipeline Products for Melanocortin Receptor 4 - Overview
  5. Pipeline Products for Melanocortin Receptor 4 - Comparative Analysis
  6. Melanocortin Receptor 4 - Therapeutics under Development by Companies
  7. Melanocortin Receptor 4 - Therapeutics under Investigation by Universities/Institutes
  8. Melanocortin Receptor 4 Products Glance
  9. Late Stage Products
  10. Clinical Stage Products
  11. Early Stage Products
  12. Melanocortin Receptor 4 - Products under Development by Companies
  13. Melanocortin Receptor 4 - Products under Investigation by Universities/Institutes
  14. Melanocortin Receptor 4 - Companies Involved in Therapeutics Development
  • AstraZeneca Plc
  • Mallinckrodt Plc
  • Obexia AG
  • Palatin Technologies, Inc.
  • Pfizer Inc.
  • Retrophin Inc.

For more information about this report visit http://www.researchandmarkets.com/research/72xh9r/melanocortin

View source version on businesswire.com: http://www.businesswire.com/news/home/20161027006460/en/

Business Wire
www.businesswire.com

Last updated on: 27/10/2016

Advertising
Share | | |
Site Map | Privacy & Security | Cookies | Terms and Conditions

PharmiWeb.com is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on PharmiWeb.com is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.